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Introduction
Adenoid cystic carcinoma (AdCC) is a malignant tumor that 
most commonly occurs in the salivary glands,1 but can occa-
sionally present in other organs, including the lung, prostate, 
skin, and breast.2–5 Unlike its head and neck counterpart, which 
shows poor long-term outcome,6 breast AdCCs have favorable 
prognosis.
Histologically, AdCC is characterized by the presence of 
mixed populations of luminal/epithelial and basal/myoepithe-
lial tumor cells, growing in tubular, cribriform, or solid growth 
patterns.7,8 Recurrent t(6;9)(q22-23;p23-24) translocation and 
the formation of the MYB-NFIB fusion gene, resulting in the 
activation and overexpression of MYB at the mRNA and pro-
tein levels is the molecular hallmark of this tumor.1,9,10 A 
minority of tumors that lack the MYB-NFIB fusion gene likely 
demonstrate activation of MYB due to molecular mechanisms 
that are yet unknown.
AdCCs are rare and account for less than 0.1% of all primary 
carcinomas of the breast.7,11,12 At times, they pose diagnostic 
difficulty due to their rarity, particularly on limited biopsy sam-
ples. Given that AdCC represents a triple-negative breast can-
cer with favorable prognosis,13 accurate diagnosis of these 
tumors is critical for appropriate clinical management. Due to 
the low prevalence of breast AdCC,14,15 its defining features are 
not well established except that these tumors display a basal-like 
phenotype13 and are commonly triple negative (estrogen recep-
tor [ER], progesterone receptor [PR], and HER-2 negative).16 
On immunohistochemical level, the basal/myoepithelial com-
ponent expresses basal markers, such as cytokeratin 14 (CK14), 
cytokeratin 17 (CK17), vimentin, epidermal growth factor 
receptor (EGFR), and p63, and the luminal/epithelial compo-
nent is positive for luminal markers, such as cytokeratin 7 
(CK7), cytokeratin 8/18 (CK8/18), epithelial membrane anti-
gen (EMA), and c-KIT (CD117).17–20
The SRY-related HMG-box 10 (SOX10) protein is a tran-
scription factor known to be crucial in the specification of the 
neural crest and maintenance of Schwann cells and melano-
cytes.21 Expression of SOX10 as a diagnostic marker has been 
previously established in salivary gland AdCC and basal-like 
breast carcinoma21,22; however, SOX-10 has not been studied in 
primary breast AdCC. In this study, we investigated the clinical, 
histological, and immunophenotypic features of breast AdCC 
and compared these features with their salivary gland and meta-
static counterparts. The goal of our study was to establish SOX-
10 as a diagnostic marker in breast AdCCs and to investigate any 
immunophenotypic differences between breast, salivary gland, 
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and metastatic AdCCs. Insight into the immunophenotype 
would also help us in understanding their cell of origin and 
potentially explain the difference in prognosis.
Materials and Methods
Case selection
Approval to perform this study was obtained from the 
Institutional Review Boards of the Human Studies Protection 
Office at Washington University (IRB No: 201502060, 
August 3, 2015). For this retrospective study, the surgical 
pathology archives of the Washington University School of 
Medicine (St Louis, MO, USA) and the St. Louis Breast 
Tumor Registry (MO, USA) were searched for breast pri-
mary AdCCs between 1992 and 2014. A total of 12 consecu-
tive cases of breast AdCCs for which formalin-fixed 
paraffin-embedded (FFPE) blocks were available were 
obtained and served as the study group; 17 age-matched sali-
vary gland AdCCs and 5 metastatic AdCCs (1 from breast 
and 4 from salivary gland) were also retrieved and served as 
the control group. The cases were centrally reviewed and the 
diagnoses were confirmed in consensus by 3 pathologists 
(CY, LZ, and SS) using current diagnostic criteria.21 Clinical 
data were collected.
Tissue microarrays
Tissue microarrays (TMAs) of 3.0 mm cores of each case were 
made in triplicate. Benign tonsil, prostate, and cerebrum tissues 
were used as controls and for slide orientation.
Immunohistochemistry
Commercially available monoclonal antibodies for SOX10, Ki-67, 
c-KIT, β-catenin, epithelial membrane antigen (EMA), p63, 
CK7, cytokeratin 5/6 (CK5/6), and androgen receptor (AR) were 
used. The immunostain information is summarized in Table 1. 
Immunohistochemical stains were performed on a Ventana 
BenchMark XT automatic stainer (Ventana Medical Systems, 
Inc, Tucson, AZ, USA), following the vendor’s protocol. Adequate 
positive and negative controls were included for each run.
The immunohistochemistry (IHC) results were interpreted 
by 3 pathologists with the following criteria: nuclear staining 
for SOX10, Ki-67, p63, and AR; membranous staining for 
EMA and β-catenin; and cytoplasmic staining for CK7, 
CK5/6, and c-KIT were considered positive. The percentage of 
cells that were positive was evaluated. For Ki-67, any nuclear 
reactivity, regardless of intensity, was considered positive. For 
AR, the Allred scoring system was used (proportion score 
0-5 + intensity score 0-3 = total score 0-8; ⩾3 positive result). 
The percentage of tumor cells labeled was collected and subse-
quently semi-quantitatively scored as 0 (no tumor cells stained), 
1+ (less than 30% of tumor cells stained), 2+ (31%-60% 
tumor cells stained), 3+ (61%-90% tumor cells stained), and 
4+ (greater than 90% tumor cells stained).
Statistical analysis
Welch t test was used to compare the intensity and percentage 
of tumor cells stained with each marker. A P value of less than 
.05 was considered statistically significant.
Results
Clinical information is summarized in Tables 2 and 3. For 
breast AdCC patients, the mean age was 58 years. In all, 11 
patients were women and 1 was man. One case of breast AdCC 
had a positive margin on resection, and all other cases had neg-
ative margins. No cases showed recurrence of disease on mean 
follow-up period of 7.7 years (range: 1-15 years). Histologically, 
3 cases showed grade I architecture, 3 cases grade II, and 6 
cases grade III with predominant solid architecture. There was 
no microglandular adenosis associated with any cases. Of cases 
with known biomarker status, 6 of 9 negative for ER, 8 of 8 
negative for PR, and 6 of 6 negative for HER2. Cases with ER 
positivity exhibited only weak and focal staining with overall 
Allred score of 3 to 4 of 8.
IHC results are summarized in Tables 4 and 5. All cases of 
breast (100%) and metastatic (100%) AdCCs and all but 2 
cases of salivary AdCCs showed diffuse nuclear staining 
(>50% of cells) for SOX10 (Figure 1). SOX10 is nondiscrimi-
natorily expressed in both the epithelial and myoepithelial 
cells. And the staining pattern did not differ with the architec-
ture grade of the tumor. Epithelial membrane antigen expres-
sion was different in breast, salivary gland, and metastatic 
AdCCs; the lowest expression (both percentage and intensity) 
was seen in breast AdCCs and the highest expression in meta-
static AdCCs (P < .01). Except one case of salivary primary 
AdCC, which showed loss of β-catenin expression and devel-
oped subsequent metastasis to the T10 vertebra, all cases of 
AdCCs showed strong and diffuse membrane β-catenin 
Table 1. Clone of antibodies used.
ANTIBODY NAME CLONE COMPANY
SOX10 Polyclonal Cell Marque, Rocklin, CA
Ki-67 30-9 Ventana, Tucson, AZ
c-KIT 9.7 Ventana, Tucson, AZ
β-catenin 14 Cell Marque, Rocklin, CA
EMA E29 Ventana, Tucson, AZ
p63 4A4 Ventana, Tucson, AZ
CK7 SP52 Ventana, Tucson, AZ
CK5/6 D5/16B4 Ventana, Tucson, AZ
AR SP107 Cell Marque, Rocklin, CA
Abbreviations: AR, androgen receptor; CK5/6, cytokeratin 5/6; CK7, cytokeratin 7; 
EMA, epithelial membrane antigen.
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expression. Androgen receptor (AR) staining in AdCCs 
showed a heterogeneic pattern, more intensive in basal cells 
than the luminal cells. The Ki-67 labeling index of breast 
AdCC ranged from 1% to 20%, with an average of 7%, not 
statistically increased compared with salivary gland AdCCs. 
There was also slight increase in Ki-67 index for metastatic 
AdCCs (P > .05). There were no significant differences in 
expression of CK7, p63, CK5/6, and c-KIT (P > .05) among 
breast, salivary gland, and metastatic AdCCs.
Discussion
Our study reinforces the indolent nature of AdCCs of the 
breast, as all 12 cases of breast AdCC in our study showed no 
evidence of metastasis to distant sites on routine clinical 
follow-up. Only one patient had a regional lymph node 
metastasis at the time of diagnosis, but was free of disease on 
1-year follow-up. Even if we consider this case as one with 
metastatic disease, the prognosis for breast AdCC is still bet-
ter than those reported for salivary gland AdCC. Our cohort 
also included a unique case of male patient with breast 
AdCC. This case showed identical clinical and histological 
characteristics as other cases of breast AdCCs. The patient 
did not show any evidence of recurrence during 12 years of 
follow-up. In explaining the different behavior of salivary 
AdCC and breast AdCC, one thing to consider is that most 
cases of breast AdCCs are resected with clear margin status 
given the anatomic approachability. However, the surround-
ing structures in the head and neck (eg, vessels, nerves, bones) 
make resection with clear margins challenging, if not impos-
sible. As a result, the margins in salivary AdCCs are com-
monly positive and could potentially be one reason for 
residual disease.
The SRY-related HMG-box 10 (SOX10) protein is a 
transcription factor known to be crucial in the specification 
Table 2. Clinicopathologic information of breast adenoid cystic carcinoma.




SIDE SIZE (CM) METASTASIS FOLLOW-UP
1. 46 F Resection Left 6.0 No 15 years, ANED
2. 53 F Resection Right 2.8 No 14 years, ANED
3. 52 F Resection Right N/A No 10 years, ANED
4. 53 F Resection Right 0.7 No 9 years, ANED
5. 60 F Resection Left 1.6 Lymph node 1 year, ANED
6. 54 F Resection N/A 1.5 No 3 years, ANED
7. 62 F Resection Left 0.9 No 7 years, ANED
8. 70 F Resection Left 0.7 No 3 years, ANED
9. 62 F Resection Right 1.8 No 3 years, ANED
10. 76 M Resection Left 3.5 No 12 years, ANED
11. N/A F Resection N/A N/A No N/A
12. N/A F Resection N/A N/A No N/A
Abbreviation: ANED, alive with no evidence of disease; F, female; M, male.
Table 3. Clinical comparison of adenoid cystic carcinoma of breast, salivary gland, and metastatic AdCC.
BREAST (N = 12) SALIVARY (N = 17) METASTATIC (N = 5)
Mean age, years (range) 58 (46-76) 53 (36-77) 56 (39-67)
Sex 1 Male/11 females 5 Males/12 females 2 Males/3 females
Mean size, cm (range) 2.2 (0.7-6.0) 4.0 (1.3-6.1) 3.1 (1.9-3.8)
Margin status 1 (+)/11 (–) 12 (+)/5 (–) 0 (+)/1 (–)a
Disease-free survival, years (range) No recurrence 2.5 (0-7) 2.5 (0-5)
Overall survival No recurrence NDRTD 1 death at 28 years
Abbreviation: NDRTD, no death related to disease.
aFour cases were biopsy and margin status is not applicable.
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of the neural crest and maintenance of Schwann cells and 
melanocytes.21 Expression of SOX10 as a diagnostic marker 
has been previously established in salivary gland AdCC, 
basal-like breast carcinoma, and benign breast myoepithelial 
cells21,22; however, SOX-10 has not been studied in primary 
breast AdCC, especially in comparison with salivary AdCC. 
We demonstrated that SOX10 is a sensitive diagnostic 
marker in all AdCCs being expressed diffusely (>50% of 
cells) in both the luminal and basal layers in 100% of cases of 
breast and metastatic AdCCs. Specifically, in cases of breast 
AdCC, most of the cases showed greater than 90% of tumor 
cell positivity for SOX10 (10 of 12 cases), where the remain-
ing 2 cases showed 60% to 90% of tumor cells positive for 
SOX10. This is extremely helpful when interpreting needle 
core biopsies or fine-needle aspiration, where only limited 
tissue is sampled. The fact that SOX10 stained both the 
Table 4. Immunohistochemistry results for breast adenoid cystic carcinoma.
CASE SOX10 (%) C-KIT (%) β-CATENIN (%) EMA (%) P63 (%) CK7 (%) CK5/6 (%) ARa (%)
1. 4+ (95) 3+ (63) 4+ (100) 0 (0) 3+ (87) 3+ (88) 4+ (100) 3 (5)
2. 4+ (100) 3+ (87) 4+ (100) 0 (0) 1+ (2) 2+ (50) 1+ (14) 4 (20)
3. 4+ (100) 1+ (30) 4+ (100) 1+ (2) 1+ (3) 4+ (100) 0 (0) 4 (30)
4. 4+ (100) 4+ (100) 4+ (100) 0 (0) 1+ (6) 2+ (53) 1+ (4) 2 (1)
5. 4+ (100) 2+ (40) 4+ (100) 1+ (1) 1+ (2) 4+ (100) 2+ (43) 0 (0)
6. 3+ (78) 2+ (45) 4+ (100) 1+ (0) 4+ (93) 3+ (80) 3+ (73) 4 (30)
7. 4+ (93) 1+ (28) 4+ (100) 1+ (0) 3+ (83) 1+ (15) 4+ (100) 4 (20)
8. 4+ (100) 3+ (90) 4+ (100) 1+ (4) 3+ (73) 4+ (100) 4+ (100) 3 (10)
9. 3+ (65) 1+ (25) 4+ (100) 1+ (5) 3+ (88) 2+ (57) 3+ (90) 4 (20)
10. 4+ (100) 4+ (100) 4+ (100) 1+ (17) 2+ (37) 4+ (100) 4+ (100) 5 (30)
11. 4+ (100) 4+ (93) 4+ (100) 1+ (2) 3+ (67) 4+ (100) 1+ (22) 4 (20)
12. 4+ (100) 3+ (70) 4+ (100) 1+ (4) 3+ (73) 3+ (75) 3+ (80) 0 (0)
Abbreviations: AR, androgen receptor.
0indicates no tumor cells stained; 1+, ⩽30% tumor cells stained; 2+, 31%-60%; 3+, 61%-90%; 4+, >90%.
aThe AR expression is interpreted using the Allred scoring system.
Table 5. Comparison of staining pattern in AdCC.













SOX10 93 (63-100) 2.23 (1-3) 83 (19-100) 2.14 (1-3) 96 (75-100) 2.50 (2-3)
c-KIT 68 (25-100) 2.19 (1-3) 61 (13-100) 1.94 (1-3) 50 (15-87) 1.67 (1-2)
β-catenin 100 (100) 2.72 (2-3) 94 (30-100) 2.41 (1-3) 100 (100) 2.50 (2-3)
EMA 3 (0-17) 0.72 (1-3) 12 (1-52) 1.49 (1-3) 34 (1-93) 2.00 (1-3)
P63 56 (2-88) 2.55 (2-3) 64 (1-97) 2.43 (1-3) 50 (2-77) 1.83 (1-3)
CK7 73 (15-100) 2.45 (1-3) 82 (6-100) 2.67 (2-3) 81 (25-100) 3.00 (3)
CK5/6 66 (0-100) 2.29 (1-3) 79 (50-100) 2.43 (1-3) 50 (5-65) 2.25 (1-3)
Ki-67 7 (1-20) N/A 6 (1-27) N/A 12 (5-25) N/A
ARa 1.9 (0-5) 1.17 (0-3) 2.02 (0-5) 0.84 (0-2) 1.58 (0-5) 0.58 (0-2)
Abbreviation: AdCC, adenoid cystic carcinoma.
aAR is interpreted using the Allred scoring system (proportion score: 0-5; intensity score 0-3).
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luminal and basal layer cell population is also helpful in that 
some cases of AdCCs show a dominant component of one 
single cell lineage. In addition, the nuclear staining pattern 
makes interpretation of staining much easier on limited 
biopsy material and fine-needle aspiration samples. While 
SOX10 is sensitive in the breast AdCCs, its utility might be 
limited when the differential diagnosis includes basal-like 
breast carcinomas, metastatic melanoma, and a small subset 
of breast invasive ductal carcinomas.13,23
In our study, we found a difference in both percentage of 
stained cells and intensity of staining for EMA in AdCCs of 
the breast when compared with other AdCCs. Noticeably, 
EMA showed intensive staining in metastatic AdCCs and 
weakest staining in breast AdCCs. Whether this pattern is 
prognostically significant is debatable, as the percentage of 
cells staining in primary lesions is low and hard to interpret on 
a daily sign-out basis. However, it is possible that with meta-
static disease, the EMA expression increases in tumor cells. It 
would be helpful to assess this difference in expression in 
paired primary-metastatic samples from the same patient. Our 
case series lacked such paired tumor-normal samples, and this 
finding could not be investigated further in our study.
β-catenin showed cytoplasmic and membranous staining in 
all but one case of AdCC. The only case that lost expression of 
β-catenin was from a patient with salivary gland AdCC that 
later developed metastasis to the T10 vertebra. This finding is 
consistent with other studies that have shown loss of membra-
nous β-catenin expression to be a poor prognostic factor in 
salivary gland AdCCs.24–26 Of note, the β-catenin status for 
the metastatic lesion in our case is unknown.
Other stains including c-KIT, p63, CK7, CK5/6, and AR all 
showed similar staining patterns among the 3 groups, suggest-
ing that these tumors share more in common than just histo-
logic features. There was a slight increase in Ki-67 proliferation 
index for the metastatic AdCCs. Previous studies have con-
cluded Ki-67 proliferation index above 4% as a poor prognostic 
factor for AdCCs of the salivary gland.27 Androgen receptor 
has been shown to be variously expressed in normal breast 
Figure 1. Immunohistochemistry staining for SOX10 and EMA in adenoid cystic carcinoma. The characteristic cribriform pattern for adenoid cystic 
carcinoma is shown in A1, B1, and C1. Strong and diffuse staining of SOX10 (red chromogen) for adenoid cystic carcinoma in both epithelial and 
myoepithelial cells is observed in breast, salivary gland, and metastatic cases (A2, B2, and C2). EMA (brown chromogen) is the only marker with gradient 
staining among breast, salivary gland, and metastatic adenoid cystic carcinomas. Only single cells are stained in this case of breast adenoid cystic 
carcinoma (A3), whereas there is more diffuse staining seen in the salivary gland tumor (B3) and diffuse staining in the metastatic tumor (C3). EMA 
indicates epithelial membrane antigen.
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ductal epithelium, serving as a good internal positive control. It 
is also usually expressed in a high proportion of breast ductal 
carcinomas; therefore, it cannot be used to confirm the diagno-
sis of AdCC versus invasive ductal carcinoma in this setting. In 
the head and neck regions, salivary duct carcinomas also show 
AR reactivity,28 and AR is used as a diagnostic tool in that set-
ting. Thus, in the salivary glands when the differential diagno-
sis includes AdCCs, AR should be interpreted with caution 
and may be a potential diagnostic pitfall. A recent study showed 
that SOX10 had negative correlation with AR in triple- 
negative breast carcinomas. However, such correlation was not 
shown in our study.29
In summary, we investigated the immunophenotypic fea-
tures of breast AdCCs in comparison with salivary gland and 
metastatic AdCCs. Despite the contrast in prognosis, our 
results indicate that these lesions have more in common immu-
nophenotypically. SOX10 is sensitive in all AdCCs, which 
could potentially be helpful in diagnosis.
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